Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Humana Inc (HUM) vs Marqeta Inc (MQ) Price & Performance

Humana IncTrade
Marqeta IncTrade

Price performance (Past 24H)

Key statistics

Humana Inc vs Marqeta Inc — how do they compare? Humana Inc trades at $437.2 (market cap $47.61B), while Marqeta Inc trades at $17.36 (market cap $1.78B). The key difference: Humana Inc is far larger — about 26.7× Marqeta Inc's market cap, and Humana Inc pays a 0.89% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Marqeta Inc for 44 Days on average.

HUMMQ
Market Cap
$47.61B$1.78B
Volume
1,827,3321,087,097
Sector
HealthTechnology
52-Week High
$409.85$20.32
52-Week Low
$163.67$15.04
Typical Hold Time
53 Days44 Days
Enterprise Value
$54.97B$1.09B
Dividend Yield
0.89%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Humana Inc

Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.

Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.

Marqeta Inc

Marqeta (MQ) trades at $17.44, up 5.38% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with three consecutive quarterly EPS beats and positive cash flow trends, though valuation remains elevated with a P/E of 189.56. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic growth initiatives.

While technical indicators suggest near-term strength, the stock faces fundamental challenges with negative net income and high valuation multiples. Analyst consensus is cautious with a $11.38 price target below current levels, indicating 31.82% buy ratings. Key risks include contract renewals in Q3 2026 and growth moderation expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM →

About Marqeta Inc

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

Read more on MQ →